Forbes Newsletters

Catch up on what you may have missed.

Forbes
All dog owners eventually come to understand one thing: The time we get to spend with these devoted pets is far too short.

But Celine Halioua thinks she can
help dogs get a few more years out of life. The scientist, Oxford Ph.D. dropout and former chief of staff at a VC fund focused on longevity has spent nearly six years building Loyal, a California-based startup developing drugs to delay canine aging.

While that might sound too good to be true, Loyal has seen real progress, and the company’s first beef-flavored
longevity pill could hit the market by next year

Halioua is already in conversations with the FDA and has cleared some early hurdles for Loyal’s drug, which
changes the metabolism of dogs ages 10 and up to mimic a low-calorie diet and has been shown to extend their lives. The company is also working on a pill and shot to lengthen the lifespans of larger dogs, which tend to be shorter.

Read more about Loyal in senior editor Amy Feldman’s latest story
here. The startup is part of Forbes’ Next Billion-Dollar Startups 2025 list, and keep scrolling below for more in-depth journalism from our newsroom.

Chris Dobstaff Associate Editor, Newsletters

Follow me on Forbes.com

Must Reads
Next Billion-Dollar Startups 2025
Longer Leash On Life: Inside The Dog Longevity Startup
Zuckerberg Squandered His AI Talent. Now He’s Spending Billions To Replace It.
Google And Pollster Scott Rasmussen Will Use AI To Survey Americans’ Political Views
Top Research Universities Hit Hard By Trump Assault On Funding, Foreign Students
Dana White On How UFC Landed Its Blockbuster $7.7 Billion Streaming Deal With Paramount
Apex Wants To Bring Henry Ford-Style Mass Production To Satellites
Inside The Richest Presidential Cabinet Ever
Uber Freight CEO Joins Waabi As Robot Truck Startup Plans Commercial Launch
Sam Altman Despises Elon Musk. Now He Is Going After His Companies
Why Warren Buffett, David Tepper And Other Top Billionaire Investors Are Piling Into Floundering UnitedHealth Stock
Meet The Mastermind Behind The $1.9 Billion Poppi Deal